system: You are a contract-analysis assistant performing a span-extraction task. You are given an excerpt from a commercial contract and the name of a clause type to locate within it.

Return the exact text of the requested clause, copied verbatim from the excerpt — identical wording and punctuation, with no paraphrasing, summarising, explanation, or added commentary.

The excerpt is one window of a much longer contract and often will not contain the requested clause. If the requested clause does not appear in this excerpt, respond with exactly: Not found.

Output only the extracted clause text, or the exact string `Not found.` — nothing else.

user: Contract excerpt:
"""
Exhibit 10.3 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. Execution Copy LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT DATED AS OF FEBRUARY 4, 2020 BY AND BETWEEN XENCOR, INC. AND AIMMUNE THERAPEUTICS, INC. Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020 TABLE OF CONTENTS Page ARTICLE 1 Definitions 1 ARTICLE 2 Licenses 13 ARTICLE 3 Development 16 ARTICLE 4 Regulatory 17 ARTICLE 5 Commercialization 19 ARTICLE 6 Supply 20 ARTICLE 7 Payments 21 ARTICLE 8 Payment; Records; Audits 24 ARTICLE 9 Intellectual Property Matters 26 ARTICLE 10 Representations, Warranties and Covenants; Compliance 31 ARTICLE 11 Indemnification 34 ARTICLE 12 Confidentiality 36 ARTICLE 13 Term and Termination 40 ARTICLE 14 Effects of Expiration Or Termination 40 ARTICLE 15 Miscellaneous 43 Schedule 1.10 Antibody 50 Schedule 1.79 Xencor General Patents 51 Schedule 1.81 Xencor Product Specific Patents 52 Schedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data 53 Schedule 6.1 Initial Product Supply 54 Schedule 10.2.6 Exceptions 55 Schedule 12.2 Initial Press Release 56 Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020 LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT This License, Development and Commercialization Agreement (this "Agreement"), dated as of February 4, 2020 (the "Effective Date"), is made by and between Xencor, Inc. ("Xencor"), and Aimmune Therapeutics, Inc. ("Aimmune"). Xencor and Aimmune are sometimes referred to herein individually as a "Party" and collectively as the "Parties". RECITALS WHEREAS, Xencor has developed the Antibody (as defined below); WHEREAS, Aimmune is interested in further developing and commercializing the Antibody; and WHEREAS, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions set forth below. NO W THEREFORE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement, and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows: ARTICLE 1 DEFINITIONS As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined elsewhere in this Agreement: 1.1 "Active Ingredient" means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure or function of the body. 1.2 "Affiliate" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with such person; provided, that, for purposes of this definition, "control" (including, with correlative meanings, the terms "controlled by" and "under common control with"), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, "person" means mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a "person" as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government. 1 Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020 1.3 "Aimmune Agreement Entities" means Aimmune's Affiliates and Sublicensees (excluding distributors). 1.4 "Aimmune Common Stock" means Aimmune's common stock, par value $0.0001 per share. 1.5 "Aimmune Field" means the field of [***]. 1.6 "Aimmune Invention" means an Invention that is Invented, solely or jointly with a Third Party, by or on behalf of Aimmune or its Affiliates. 1.7 "Aimmune Know-How" means any and all Know-How, whether or not patented or patentable, that is Controlled by Aimmune or its Affiliates as of the Effective Date or at any time during the Term that is necessary or reasonably useful in connection with the Development, Manufacture, Commercialization or other use of the
"""

Extract the exact clause related to "Document Name" from the excerpt above.

assistant: LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT